NBIX
USDNeurocrine Biosciences Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$141.970
Kõrge
$143.870
Madal
$140.820
Maht
0.26M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
14.3B
Tööstusharu
Drug Manufacturers - Specialty & Generic
Riik
United States
Kauplemisstatistika
Keskmine maht
0.86M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Truist Securities Reiterates Buy on Neurocrine Biosciences, Raises Price Target to $172
Truist Securities analyst Danielle Brill reiterates Neurocrine Biosciences with a Buy and raises the price target from $165 to $172.
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $164
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences with a Buy and raises the price target from $160 to $164.
Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $183
Stifel analyst Paul Matteis maintains Neurocrine Biosciences with a Buy and raises the price target from $174 to $183.
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $160
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences with a Outperform and raises the price target from $156 to $160.
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $179
Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences with a Overweight and raises the price target from $175 to $179.
Needham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $184
Needham analyst Ami Fadia maintains Neurocrine Biosciences with a Buy and raises the price target from $170 to $184.
UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $195
UBS analyst Ashwani Verma maintains Neurocrine Biosciences with a Buy and raises the price target from $188 to $195.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.